Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals develops oral antiviral therapeutics for serious viral diseases. The company uses a proprietary nucleos(t)ide prodrug platform focused on single-stranded RNA viruses and is building a pipeline that includes bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for hepatitis C virus treatment.
Recurring Atea news covers clinical and preclinical antiviral development, including HCV Phase 3 studies such as C-BEYOND and C-FORWARD, hepatitis E virus candidates including AT-587 and AT-2490, scientific conference presentations, financial results, and business updates tied to pipeline execution.
Atea Pharmaceuticals (AVIR) announced a live conference call for August 8, 2022, at 4:30 p.m. ET to discuss its Q2 financial results and provide a business update. The company focuses on developing oral antiviral therapies for severe viral diseases, including COVID-19 and hepatitis C. This event will be accessible via registration and a live webcast on their investor relations website. Atea emphasizes its commitment to advancing its nucleos(t)ide prodrug platform for treating RNA viruses. They also caution about risks associated with forward-looking statements.
Atea Pharmaceuticals (Nasdaq: AVIR) announced participation in the William Blair Biotech Focus Conference, with a pre-recorded fireside chat available from July 11, 2022, at 9:00 a.m. ET. The company focuses on developing oral antiviral therapies for severe diseases, utilizing its proprietary nucleos(t)ide prodrug platform. Current efforts include treatments for COVID-19, hepatitis C, dengue, and RSV. Atea emphasizes its commitment to advancing antiviral candidates through ongoing research and development.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi will present a corporate overview at the Jefferies Healthcare Conference on June 8, 2022, at 11:00 a.m. ET. A live webcast will be accessible on their website, and a replay will be available for 90 days. Atea is a clinical-stage biopharmaceutical company focused on developing oral antiviral therapies for serious diseases, including COVID-19 and HCV, utilizing its proprietary nucleos(t)ide prodrug platform. The company emphasizes its commitment to addressing unmet medical needs in severe viral infections.
Atea Pharmaceuticals (AVIR) announced new clinical results from the MORNINGSKY trial, indicating a 71% reduction in hospitalization for COVID-19 patients treated with bemnifosbuvir (AT-527) compared to placebo (p=0.047). The Phase 2 study in high-risk patients also showed no deaths among those treated with bemnifosbuvir. The company initiated a Phase 2 global study for AT-752 targeting dengue and is preparing for a combination study of bemnifosbuvir and ruzasvir for hepatitis C in 2H 2022. Atea reported a net loss of $42.1 million for Q1 2022.
Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call on May 10, 2022, at 8:00 a.m. ET to share financial results for Q1 ended March 31, 2022, and provide a business update. Investors can access the call by dialing (800) 343-5172 domestically or (203) 518-9814 internationally, with conference ID AVIRQ122. A live audio webcast and slide presentation will be available on Atea's website.
Atea focuses on developing oral antiviral therapies for severe viral diseases, including COVID-19 and hepatitis C.
Atea Pharmaceuticals presented favorable nonclinical data for bemnifosbuvir (AT-527) at the SOT 61st Annual Meeting in San Diego. The company reported a nonclinical safety profile with no reproductive or developmental toxicity in animal models. This includes:
- No effects on fertility or reproduction in rats.
- No embryofetal abnormalities in rabbits at high doses.
- Low potential for QTc prolongation in both rats and monkeys.
CEO Jean-Pierre Sommadossi emphasized its suitability for clinical development against severe viral infections, including COVID-19 and hepatitis C.
Atea Pharmaceuticals (Nasdaq: AVIR) reported strong financial results for Q4 and the full year 2021, with collaboration revenue of $192.2 million and total revenue of $351.4 million, significantly up from $48.6 million in 2020. The net income was $117.1 million, compared to $20.7 million in the previous year. Atea is advancing three Phase 2 programs targeting COVID-19, hepatitis C, and dengue fever, and anticipates important milestones in 2022. With cash reserves of $764.4 million, the company is well-positioned to fund ongoing developments.
Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call and audio webcast on February 28, 2022, at 4:30 p.m. ET. This event will report the fourth-quarter and full-year financial results for 2021, and provide a business update. Atea, focused on developing oral therapies for severe viral diseases, aims to address unmet medical needs, particularly for infections like COVID-19 and hepatitis C. Following the live call, an archived version will be accessible on the company’s website.
Atea Pharmaceuticals has appointed Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development, enhancing its expertise in drug discovery and development. Dr. Agrawal, with over 25 years of experience at Merck, replaces Steven Good, who will retire this year. Her extensive background in developing antivirals aligns with Atea's mission to create oral therapies for severe viral diseases. The company is focused on expanding its pipeline, including treatments for COVID-19, hepatitis C, dengue, and RSV.
BOSTON, Feb. 09, 2022 – Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi and the management team will present a business update at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 2:20 p.m. ET. A live webcast of the event will be accessible on the company’s website, with a replay available for 90 days. Atea focuses on developing oral therapies for severe viral diseases, including SARS-CoV-2 and hepatitis C, utilizing a proprietary nucleotide prodrug platform.